Aurobindo Pharma Gets Exclusive Rights For Biofactura 39 S Monoclonal Antibody Ustekinumab Biosimilar

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Aurobindo Pharma arm gets exclusive rights for BioFactura monoclonal antibody ustekinumab biosimilar

ri-calendar-2-lineJul 10, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Aurobindo Pharma Ltd., a prominent pharmaceutical company, announced on Friday, July 7, that CuraTeQ Biologics Private, a wholly-owned subsidiary, has inked an exclusive licencing deal with the US-based BioFactura to commercialise BFI-751, a potential biosimilar to Stelara.

Ustekinumab is a recombinant monoclonal antibody used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It acts by blocking the interleukins IL-12 and IL-23.

Ustekinumab had close to $10 billion in global medication sales in 2022, the business reported in an exchange filing, offering a sizable prospect with a good range of indications and wider use.

According to the terms of the agreement, CuraTeQ has been given the sole right to commercialise BFI-751 in the US, EU, UK, Canada, ANZ, and a few other semi-regulated and developing markets across the world. The product will be manufactured at CuraTeQ facilities in Hyderabad, India, and will also have global manufacturing rights, according to the business.

Source: Media reports

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartCommodities

Why Gold Remains a Safe Haven Amid Global Economic Shifts in 2025

0 people read

4 mins read . Sep 5, 2025

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions